We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GSK525762 in subjects with relapsed, refractory hematologic malignancies
Previous Study | Return to List | Next Study

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

This study is currently recruiting participants.
Verified November 2017 by GlaxoSmithKline
Sponsor:
ClinicalTrials.gov Identifier:
NCT01943851
First Posted: September 17, 2013
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 24, 2020
  Estimated Primary Completion Date: February 26, 2018 (Final data collection date for primary outcome measure)